RETRACTED: Multi‐Stimuli Nanocomposite Therapeutic: Docetaxel Targeted Delivery and Synergies in Treatment of Human Breast Cancer Tumor
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Dossier post-publication
- Nature
- Retraction
- Motif
- Concerns/Issues about Image;Concerns/Issues about Animal Welfare;Euphemisms for Plagiarism;Investigation by Journal/Publisher;Lack of IRB/IACUC Approval and/or Compliance;Plagiarism of Image;Unreliable Data;Unreliable Results and/or Conclusions;
- Date
- 8/12/2024 0:00
- Signalé par OpenAlex ?
- Oui
Source : Retraction Watch, jointe par DOI. OpenAlex consigne la rétractation dans is_retracted, un booléen sur un espace d'états à au moins quatre valeurs ; il ne peut donc exprimer ni une expression de préoccupation, ni une correction, ni un rétablissement, et les rapporte comme false, ce qui se lit comme « rien à signaler ».
Résumé
Abstract A versatile breast cancer‐targeting nanocomposite therapeutic combining docetaxel (DXL), polyvinyl alcohol (PVA) network for controlled release, and silica‐protected magnetic iron oxide nanoparticles (Fe 3 O 4 NPs) for targeted delivery and gold nanoparticles (AuNPs) for plasmonic photothermal therapy (PPTT) is presented in this work. First, the designed nanocomposite is magnetically directed for cancer‐targeted therapy confirmed by computerized tomography (CT) scans. Second, 10% DXL by mass is loaded into PVA, a pH and temperature responsive gel, for controlled release. Third, PPTT is confirmed with Au/Fe 3 O 4 /PVA‐10%DXL using a prototype circulation system and then for tumor treatment in vivo; Au/Fe 3 O 4 /PVA‐10%DXL is conveniently directed and the entrapped DXL is selectively released (≈96%) via the interaction of green and near‐infrared (NIR) light with the localized surface plasmon resonance of AuNPs. A 75% cell death is reported from in vitro studies with DXL doses as low as 20 µg mL −1 of Au/Fe 3 O 4 /PVA‐10%DXL, and a 70% tumor growth inhibition is demonstrated by in vivo experiments with the biosafety studies confirming minimal side effects to other organs. Overall, the developed Au/Fe 3 O 4 /PVA‐10%DXL has a strong potential to simultaneously enhance CT imaging contrast together with the targeted delivery of DXL.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- Small
- Thématique
- Nanoparticle-Based Drug Delivery
- Domaine
- Materials Science
- Établissements canadiens
- Wilfrid Laurier University
- Organismes subventionnaires
- West China Hospital, Sichuan University
- Mots-clés
- DocetaxelNanocompositePolyvinyl alcoholBreast cancerNanoparticleMaterials scienceMetastatic breast cancerCancerIron oxide nanoparticlesMedicineMagnetic nanoparticlesNanotechnologyCancer researchOncologyInternal medicineComposite material
- Résumé présent dans OpenAlex
- oui